Search Results

No Results

    See all results

    Sorry, I don't understand. Please try again
    1. United States/
    2. Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations

    Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations

    June 7, 2022
    June 7, 2022

    Download the PDF